AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32182127 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Iliotibial Band Tenodesis (MITBT) added to ACL reconstruction (group B)
Number of subjects: 55
Study 32182127 — intervention group
Group type: COMPARATOR
Intervention: No further surgery (group A)
Number of subjects: 55
Study 35141898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDEX)
Number of subjects: 58
Study 35141898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34637889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed CRDPs
Number of subjects: 15
Study 34637889 — intervention group
Group type: COMPARATOR
Intervention: Milled CRDPs
Number of subjects: 15
Study 34637889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both milled and 3D-printed CRDPs
Number of subjects: 15
Study 35042057 — intervention group
Group type: EXPERIMENTAL
Intervention: Talus mobilization-based manual therapy (six sessions of anteroposterior talus mobilization)
Number of subjects: 42
Study 35042057 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 42
Study 32271521 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal stereopsis
Number of subjects: 0
Study 32271521 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial stereopsis (150 seconds of arc)
Number of subjects: 0
Study 32271521 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent stereopsis
Number of subjects: 0
Study 32271521 — intervention group
Group type: COMPARATOR
Intervention: Partial stereopsis
Number of subjects: 0
Study 36455187 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20 mg/m2/d days 1‐5
Number of subjects: 170
Study 36455187 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HY) 1‐4 g/d
Number of subjects: 170
Study 36455187 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 170
Study 36455187 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (HY)
Number of subjects: 170
Study 36332333 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐Exercise Low Back Pain (self-management intervention)
Number of subjects: 0
Study 32168870 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 20
Study 32168870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35526605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg dose, oral)
Number of subjects: 45
Study 35526605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 45
Study 33332778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined REGN-COV2 dose groups (2.4 g and 8.0 g)
Number of subjects: 275
Study 33332778 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 275
Study 32203231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread with 58FeSO4 consumed with TK
Number of subjects: 17
Study 32203231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified bread with 57FeFum consumed with TK
Number of subjects: 17
Study 32203231 — intervention group
Group type: COMPARATOR
Intervention: Fortified bread with 58FeSO4 consumed with water
Number of subjects: 17
Study 32203231 — intervention group
Group type: COMPARATOR
Intervention: Fortified bread with 57FeFum consumed with water
Number of subjects: 17
Study 35393332 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine physiotherapy input plus a simple exercise programme completed individually by the patient
Number of subjects: 0
Study 35393332 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy input
Number of subjects: 0
Study 34167284 — intervention group
Group type: EXPERIMENTAL
Intervention: New dressing (ND) group - self‐developed low‐temperature boric acid wet dressing, 3 times a day
Number of subjects: 100
Study 34167284 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing (CD) group - normal temperature boric acid solution wet dressing, 3 times a day
Number of subjects: 100
Study 33028661 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment of COVID-19 (specific details not provided)
Number of subjects: 1
Study 33028661 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1
Study 35059187 — intervention group
Group type: COMPARATOR
Intervention: Group A received a standard recommended maintenance dose of 2000 IU daily
Number of subjects: 230
Study 35059187 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B received 125 IU/kg/m2 of vitamin D3
Number of subjects: 230
Study 33759644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) applied for 90 min
Number of subjects: 21
Study 33759644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP)
Number of subjects: 21
Study 33687070 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 169500
Study 36376399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag NPs at 25 µg/mL
Number of subjects: 5
Study 36376399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag NPs at 50 µg/mL
Number of subjects: 5
Study 36376399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag NPs at 100 µg/mL
Number of subjects: 5
Study 36376399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ag NPs at 250 µg/mL
Number of subjects: 5
Study 36376399 — intervention group
Group type: COMPARATOR
Intervention: Untreated sample
Number of subjects: 5
Study 34741370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based virtual reality (VR) program (Take-Pause) for 5 minutes
Number of subjects: 110
Study 34741370 — intervention group
Group type: COMPARATOR
Intervention: Passive distraction intervention (iPad group) for 5 minutes
Number of subjects: 110
Study 34741370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based virtual reality (VR) program (Take-Pause)
Number of subjects: 110
Study 34741370 — intervention group
Group type: COMPARATOR
Intervention: Passive distraction intervention (iPad group)
Number of subjects: 110
Study 32646941 — intervention group
Group type: EXPERIMENTAL
Intervention: ANGPTL3 inhibition
Number of subjects: 0
Study 35775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic‐assisted anorectoplasty (LAARP)
Number of subjects: 16
Study 35775517 — intervention group
Group type: COMPARATOR
Intervention: Open posterior sagittal anorectoplasty (PSARP)
Number of subjects: 16
Study 34140199 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-accessible computer role-playing game intervention
Number of subjects: 240
Study 34140199 — intervention group
Group type: COMPARATOR
Intervention: Control condition (list of resources)
Number of subjects: 240
Study 35470199 — intervention group
Group type: EXPERIMENTAL
Intervention: Open dialogue about complementary and alternative medicine (OD‐CAM)
Number of subjects: 207
Study 35470199 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 207
Study 33451308 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text-messages intervention (StAR2D)
Number of subjects: 0
Study 33451308 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34348719 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Steps app
Number of subjects: 23
Study 32445440 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days)
Number of subjects: 1062
Study 32445440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 32445440 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 1062
Study 35081799 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation group (Group 1)
Number of subjects: 93
Study 35081799 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation group (Group 2)
Number of subjects: 93
Study 33926246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent self-reported responses
Number of subjects: 2967
Study 33926246 — intervention group
Group type: COMPARATOR
Intervention: Parent-reported responses
Number of subjects: 2967
Study 32353174 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week physical activity intervention
Number of subjects: 132
Study 32353174 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 132
Study 35907370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (40 ml)
Number of subjects: 70
Study 35907370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%, 40 ml)
Number of subjects: 70
Study 32918459 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI above normal
Number of subjects: 1684
Study 32918459 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 1684
Study 32918459 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI above normal and obesity
Number of subjects: 1684
Study 32687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaboration
Number of subjects: 518
Study 32687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred communication methods
Number of subjects: 518
Study 32687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived roles of pharmacists
Number of subjects: 518
Study 32687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived barriers to collaboration
Number of subjects: 518
Study 32687539 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of collaboration potential
Number of subjects: 518
Study 36128889 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin intervention (combined folic acid 200 μg, vitamin B12 10 μg, vitamin B6 10 mg, riboflavin 5 mg)
Number of subjects: 205
Study 36128889 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin intervention
Number of subjects: 205
Study 36128889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (active placebo with vitamin D 10 μg)
Number of subjects: 205
Study 34863304 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma in addition to standard of care
Number of subjects: 31
Study 34863304 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 31
Study 34863304 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma group
Number of subjects: 31
Study 34863304 — intervention group
Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 31
Study 36471399 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGASUS program (intervention)
Number of subjects: 16
Study 36471399 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 16
Study 33266022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (200,000 IU bolus at week 0 followed by 20,000 IU/day for 7 weeks)
Number of subjects: 40
Study 33266022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D combined with infliximab (5 mg/kg at weeks 0, 2, and 6)
Number of subjects: 40
Study 33266022 — intervention group
Group type: COMPARATOR
Intervention: Infliximab alone (5 mg/kg at weeks 0, 2, and 6)
Number of subjects: 40
Study 33266022 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-infliximab + vitamin D
Number of subjects: 40
Study 33266022 — intervention group
Group type: COMPARATOR
Intervention: Placebo-infliximab + placebo-vitamin D
Number of subjects: 40
Study 36228567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia berry (poly)phenol supplementation
Number of subjects: 102
Study 36228567 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin placebo)
Number of subjects: 102
Study 33933189 — intervention group
Group type: EXPERIMENTAL
Intervention: People living with HIV
Number of subjects: 2017
Study 33933189 — intervention group
Group type: COMPARATOR
Intervention: People without HIV
Number of subjects: 2017
Study 33760368 — intervention group
Group type: COMPARATOR
Intervention: Gout patients
Number of subjects: 330
Study 33760368 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic hyperuricemia patients
Number of subjects: 330
Study 33760368 — intervention group
Group type: COMPARATOR
Intervention: Normouricemic controls
Number of subjects: 330
Study 33760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate diagnostic model using MUVR
Number of subjects: 330
Study 33760368 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (random forest, support vector machine, logistic regression)
Number of subjects: 330
Study 33531522 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 117
Study 33531522 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Interval Training (MIIT)
Number of subjects: 117
Study 33531522 — intervention group
Group type: COMPARATOR
Intervention: Inactive Control Group
Number of subjects: 117
Study 32693310 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Performance (KP) feedback
Number of subjects: 14
Study 32693310 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of Results (KR) + Knowledge of Performance (KP) feedback on 1 day per week and KR feedback on the other 3 days per week
Number of subjects: 14
Study 34732114 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX plus midazolam (DM group)
Number of subjects: 50
Study 34732114 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX plus propofol (DP group)
Number of subjects: 50
Study 34732114 — intervention group
Group type: COMPARATOR
Intervention: Both groups (DM and DP)
Number of subjects: 50
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µg hepatitis B vaccination
Number of subjects: 182
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccination
Number of subjects: 182
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in patients with CD4 <350 cells/µl
Number of subjects: 182
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in patients with CD4 ≥350 cells/µl
Number of subjects: 182
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up from 6 months to 3 years after vaccination in patients with CD4 <350 cells/µl
Number of subjects: 182
Study 34814584 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up from 6 months to 3 years after vaccination in patients with CD4 ≥350 cells/µl
Number of subjects: 182
Study 33672197 — intervention group
Group type: EXPERIMENTAL
Intervention: No self-perceived need of dental care
Number of subjects: 344
Study 33672197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower DMFT index
Number of subjects: 344
Study 33672197 — intervention group
Group type: COMPARATOR
Intervention: Frequent tooth-brushing (18.4% reported)
Number of subjects: 344
Study 33672197 — intervention group
Group type: COMPARATOR
Intervention: Need for dental care (39.9% reported)
Number of subjects: 344
Study 32111701 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth coaching intervention (phone calls every 2 weeks for 3 months, followed by 3 months of tailored text messages)
Number of subjects: 80
Study 32111701 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 3 months, followed by nontailored educational text messages for 3 months
Number of subjects: 80
Study 32111701 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth coaching intervention
Number of subjects: 80
Study 32776988 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 10
Study 36419043 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Low-dose CT scans and 3D models printed before inexperienced surgeons performed surgeries
Number of subjects: 80
Study 36419043 — intervention group
Group type: COMPARATOR
Intervention: Group B: Standard-dose CT scans and 3D models printed before experienced surgeons performed surgeries
Number of subjects: 80
Study 36419043 — intervention group
Group type: COMPARATOR
Intervention: Group C: Standard-dose CT scans, operations performed by inexperienced surgeons
Number of subjects: 80
Study 36419043 — intervention group
Group type: COMPARATOR
Intervention: Group D: Standard-dose CT scans, operations performed by experienced surgeons
Number of subjects: 80
Study 34652861 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 132
Study 34652861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 34652861 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 132
Study 32012257 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Adolescents (FFT-A) - 21 sessions
Number of subjects: 144
Study 32012257 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (EC) - 3 sessions
Number of subjects: 144
Study 32012257 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment for Adolescents (FFT-A)
Number of subjects: 144
Study 32012257 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (EC)
Number of subjects: 144
Study 36169179 — intervention group
Group type: EXPERIMENTAL
Intervention: Early referral to palliative care
Number of subjects: 15
Study 36169179 — intervention group
Group type: COMPARATOR
Intervention: Discretionary referral to palliative care
Number of subjects: 15
Study 36279930 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 2467
Study 36279930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2467
Study 32854751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 400
Study 32854751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 33441158 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day Omega-3 supplementation (N-3, n = 7)
Number of subjects: 14
Study 33441158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA, n = 7)
Number of subjects: 14
Study 33441158 — intervention group
Group type: EXPERIMENTAL
Intervention: N-3 supplementation (n = 7)
Number of subjects: 14
Study 32083365 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cardioverter-defibrillator (WCD) compliance
Number of subjects: 0
Study 32083365 — intervention group
Group type: EXPERIMENTAL
Intervention: WCD compliance predictors
Number of subjects: 0
Study 34431196 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out delivery of point-of-care (POC) HIV-1 nucleic acid testing (NAAT)
Number of subjects: 2874
Study 34431196 — intervention group
Group type: COMPARATOR
Intervention: Standard provider-initiated HIV testing using rapid tests
Number of subjects: 2874
Study 34015241 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times per week
Number of subjects: 25
Study 34015241 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times per week
Number of subjects: 25
Study 33891328 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 48
Study 33891328 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 48
Study 36002117 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 mg ASA orally once daily from D 120 until parturition (group ASA1)
Number of subjects: 16
Study 36002117 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 mg ASA orally twice daily from D 285 until parturition (group ASA2)
Number of subjects: 16
Study 36002117 — intervention group
Group type: COMPARATOR
Intervention: 5,000 mg lactose orally once daily from D 120 until parturition (group C)
Number of subjects: 16
Study 32663269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge Expansion (RE)
Number of subjects: 12
Study 32663269 — intervention group
Group type: COMPARATOR
Intervention: Non-Ridge Expansion (NE) Control
Number of subjects: 12
Study 32160058 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐body cryotherapy (WBC)
Number of subjects: 12
Study 32160058 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast‐water therapy (CWT)
Number of subjects: 12
Study 32160058 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 35051263 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 153
Study 35051263 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 153
Study 35051263 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 153
Study 32207354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory cytokines (IL-6, IL-12p70, IL-17, TNF-α)
Number of subjects: 50
Study 32207354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory cytokines (IL-10, TGF-β1)
Number of subjects: 50
Study 32207354 — intervention group
Group type: COMPARATOR
Intervention: Cytokine levels among survivors and nonsurvivors
Number of subjects: 50
Study 32207354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels correlation with SOFA and VIS
Number of subjects: 50
Study 33947195 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri (DSM 17938 and ATCC PTA 6475)
Number of subjects: 80
Study 33947195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care plans established before pneumonia
Number of subjects: 429
Study 35932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in advance care plans after pneumonia
Number of subjects: 429
Study 35932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in treatment plans after pneumonia
Number of subjects: 429
Study 35932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of illness
Number of subjects: 429
Study 35932798 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of family members in decision making
Number of subjects: 429
Study 33662285 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy in 40 fractions of thoracic radiotherapy
Number of subjects: 170
Study 33662285 — intervention group
Group type: COMPARATOR
Intervention: 45 Gy in 30 fractions of thoracic radiotherapy
Number of subjects: 170
Study 35189750 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS! teacher-implemented
Number of subjects: 281
Study 35189750 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS! community aide-implemented
Number of subjects: 281
Study 35189750 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 281